Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.11 (market cap $119.10M), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 639.3× Roundhill NVDA WeeklyPay ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 50 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NVDW | REGN | |
|---|---|---|
Market Cap | $119.10M | $76.14B |
Volume | 44,838 | 500,239 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $852.03 |
52-Week Low | $31.88 | $557.73 |
Typical Hold Time | 50 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $37.11, down 4.11% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF provides weekly dividend income tied to Nvidia's performance with 120% leveraged exposure. Recent Nvidia earnings beat expectations, supporting the AI theme's momentum, though the fund carries elevated risk due to leverage and NAV volatility during Nvidia downturns.
The outlook remains tied to Nvidia's AI-driven growth, offering high-yield income potential but with significant volatility risk. Investors face exposure to Nvidia's stock performance amplified by leverage, making the fund suitable for risk-tolerant income seekers but vulnerable to sharp corrections in the underlying asset.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
